发明名称 |
Na+/K+-ATPase-specific peptide inhibitors/activators of Src and Src family kinases |
摘要 |
A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogs, and is pathway (Na+/K+-ATPase) specific. |
申请公布号 |
US8981051(B2) |
申请公布日期 |
2015.03.17 |
申请号 |
US201213625162 |
申请日期 |
2012.09.24 |
申请人 |
The University of Toledo |
发明人 |
Xie Zi-Jian;Shapiro Joseph I.;Tian Jiang;Li Zhichuan |
分类号 |
A61K38/10;C07K14/47;A61K38/45;A61K38/46;C07K7/08;G01N33/573 |
主分类号 |
A61K38/10 |
代理机构 |
MacMillan, Sobanski & Todd, LLC |
代理人 |
MacMillan, Sobanski & Todd, LLC |
主权项 |
1. A pharmaceutical composition for regulation of one or more signaling pathways involved in fibrosis, the composition comprising:
one or more Src and Src family kinases inhibitors comprised of one or more isolated peptides, or fragments thereof, that do not inhibit the ion pumping function of Na+/K+-ATPase; wherein the one or more isolated peptides comprises the active isolated Src-inhibitory peptide (P3) consisting of the amino acid sequence of SEQ ID NO: 2. |
地址 |
Toledo OH US |